Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aTAC BEAM Regimen in T-Cell Non-Hodgkin Lymphoma
NCT02342782Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yttrium Y 90-labeled basiliximab in mature T-cell non-Hodgkin lymphoma (PTCL), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose and Incidence of Toxicities. Started Jun 2020; status: completed.
02
Drugs
yttrium Y 90-labeled basiliximab
03
Conditions
mature T-cell non-Hodgkin lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02342782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342782.